It is this life cycle that makes Lm an ideal candidate to deliver antigen to both the MHC I and II pathways, activating CD4+ T cells and, most importantly for tumor-lytic responses, cytotoxic CD8+ T cells (24). The gene discussed is CD8A; the disease is neoplasm.